Deutsche Bank analyst Gregg Gilbert says he does not see the justification to downgrade Endo International after the company issued a weaker than expected 2016 outlook amid generic competitive and pricing pressures. In a research note tiled "Surprised, disappointed, nervous; not downgrading here," Gilbert tells investors that he sees the potential for Endo shares to be significantly higher in 12 months. "Rightly or wrongly we are choosing to take the view that significant risk is priced in at these levels," the analyst writes. He cut his price target for Endo shares to $31 from $61 and keeps a Buy rating on the name. The stock closed Friday down 39%, or $10.42, to $16.17.